19 / 30
SA JOURNAL OF DIABETES & VASCULAR DISEASE
RESEARCH ARTICLE
VOLUME 17 NUMBER 2 • NOVEMBER 2020
55
such as hyperglycaemia. The mechanisms underlying the
attenuation of cardiac dysfunction in chronic diabetes mellitus by
Mg
2+
were unrelated to electrocardiographically or histologically
detectable changes, but the exact pathways involved require
further investigation.
The study was supported by the South African Medical Research
Council (MRC, Grant No 29841) and by the National Research
Foundation (NRF) of South Africa (Grant No 91514).
References
1. Beckman JA, Creager MA. Vascular complications of diabetes.
Circ Res
2016;
118
(11): 1771–1785.
2. Deluyker D, Evens L, Bito V. Advanced glycation end products (AGEs) and
cardiovascular dysfunction: focus on high molecular weight AGEs.
Amino Acids
2017;
49
(9): 1535–1541.
3. Hu X, Bai T, Xu Z, Liu Q, Zheng Y, Cai L. Pathophysiological fundamentals of
diabetic cardiomyopathy.
Compr Physiol
2017;
7
(2): 693–711.
4. Peterson LR, McKenzie CR, Schaffer JE. Diabetic cardiovascular disease: getting to
the heart of the matter.
J Cardiovasc Transl Res
2012;
5
(4): 436–445.
5. Forbes JM, Cooper ME. Mechanisms of diabetic complications.
Physiol Rev
2013;
93
(1): 137–188.
6. Grundy SM, Benjamin IJ, Burke GL,
et al
. Diabetes and cardiovascular disease:
a statement for healthcare professionals from the American Heart Association.
Circulation
1999;
100
(10): 1134–1146.
7. Liamis G, Liberopoulos E, Barkas F, Elisaf M. Diabetes mellitus and electrolyte
disorders.
World J Clin Cases
2014;
2
(10): 488–496.
8. Sjogren A, Floren CH, Nilsson A. Magnesium deficiency in IDDM related to level
of glycosylated hemoglobin.
Diabetes
1986;
35
(4): 459–463.
9. Atabek ME, Kurtoglu S, Pirgon O, Baykara M. Serum magnesium concentrations
in type 1 diabetic patients: relation to early atherosclerosis.
Diabetes Res Clin
Pract
2006;
72
(1): 42–47.
10. Nagase N. Hypertension and serumMg in the patients with diabetes and coronary
heart disease.
Hypertens Res
1996;
19
( Suppl 1): S65–68.
11. Del Gobbo LC, Song Y, Poirier P, Dewailly E, Elin RJ, Egeland GM. Low serum
magnesium concentrations are associated with a high prevalence of premature
ventricular complexes in obese adults with type 2 diabetes.
Cardiovasc Diabetol
2012; 1123.
12. Morakinyo AO, Samuel TA, Adekunbi DA. Magnesium upregulates insulin
receptor and glucose transporter-4 in streptozotocin-nicotinamide-induced
type-2 diabetic rats.
Endocr Regul
2018;
52
(1): 6–16.
13. Mubagwa K, Gwanyanya A, Zakharov S, Macianskiene R. Regulation of cation
channels in cardiac and smooth muscle cells by intracellular magnesium.
Arch
Biochem Biophys
2007;
458
(1): 73–89.
14. Amoni M, Kelly-Laubscher R, Blackhurst D, Gwanyanya A. Beneficial effects of
magnesium treatment on heart rate variability and cardiac ventricular function in
diabetic rats.
J Cardiovasc Pharmacol Ther
2017;
22
(2): 169–178.
15. Sameshima H, Ota A, Ikenoue T. Pretreatment with magnesium sulfate protects
against hypoxic-ischemic brain injury but postasphyxial treatment worsens brain
damage in seven-day-old rats.
Am J Obstet Gynecol
1999;
180
(3 Pt 1): 725–730.
16. Amoni M, Kelly-Laubscher R, Petersen M, Gwanyanya A. Cardioprotective
and anti-arrhythmic effects of magnesium pretreatment against ischaemia/
reperfusion injury in isoprenaline-induced hypertrophic rat heart.
Cardiovasc
Toxicol
2017;
17
(1): 49–57.
17. Buwa CC, Mahajan UB, Patil CR, Goyal SN. Apigenin attenuates betareceptor-
stimulated myocardial injury via safeguarding cardiac functions and escalation of
antioxidant defence system.
Cardiovasc Toxicol
2016;
16
(3): 286–297.
18. Raev DC. Which left ventricular function is impaired earlier in the evolution of
diabetic cardiomyopathy? An echocardiographic study of young type I diabetic
patients.
Diabetes Care
1994;
17
(7): 633–639.
19. Litwin SE, Raya TE, Anderson PG, Daugherty S, Goldman S. Abnormal cardiac
function in the streptozotocin-diabetic rat. Changes in active and passive
properties of the left ventricle.
J Clin Invest
1990;
86
(2): 481–488.
20. Mihm MJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyopathy time
dependent echocardiographic evaluation in an experimental rat model.
Life Sci
2001;
69
(5): 527–542.
21. Wei M, Ong L, Smith MT,
et al
. The streptozotocin-diabetic rat as a model of the
chronic complications of human diabetes.
Heart Lung Circ
2003;
12
(1): 44–50.
22. Liu M, Jeong EM, Liu H,
et al
. Magnesium supplementation improves diabetic
mitochondrial and cardiac diastolic function.
JCI Insight
2019;
4
(1): e123182.
23. Nikolajevic Starcevic J, Janic M, Sabovic M. Molecular Mechanisms Responsible
for Diastolic Dysfunction in Diabetes Mellitus Patients.
Int J Mol Sci
2019;
20
(5):
1197.
24. Radovits T, Korkmaz S, Matyas C,
et al.
An altered pattern of myocardial
histopathological and molecular changes underlies the different characteristics
of type-1 and type-2 diabetic cardiac dysfunction.
J Diabetes Res
2015;
2015
:
728741.
25. van Heerebeek L, Hamdani N, Handoko ML,
et al.
Diastolic stiffness of the failing
diabetic heart: importance of fibrosis, advanced glycation end products, and
myocyte resting tension.
Circulation
2008;
117
(1): 43–51.
26. Sanyal SN, Wada T, Yamabe M,
et al
. Synaptic degradation of cardiac autonomic
nerves in streptozotocin-induced diabetic rats.
Pathophysiology
2012;
19
(4):
299–307.
27. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and preeclampsia:
pharmacokinetic principles.
Clin Pharmacokinet
2000;
38
(4): 305–314.
SUSTAINED
RELEASE
METABOLICALLY
NEUTRAL
1
DYNA INDAPAMIDE SR.
Each tablet contains 1,5 mg indapamide. S3 A42/7.1/0790. NAM NS2 12/7.1/0138.
For full prescribing information, refer to the professional information approved by SAHPRA, 25 November
2011.
1)
Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension.
Drug
Safety
2001;24(15):1155-1165.
DINF624/10/2019.
only generic
1,5 mg
sustained release
formulation
CUSTOMER CARE LINE
0860 PHARMA (742 762) / +27 21 707 7000
www.pharmadynamics.co.za